• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Mekonos

Wednesday, June 05, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
Mekonos is using its novel cell-engineering platform to create a future where personalized medicine is accessible to all. By combining cutting-edge semiconductor technology, microfluidics, and proprietary surface chemistry, Mekonos' platform enables the ex vivo delivery of any molecular cargo to any cell. Mekonos' non-viral approach offers unprecedented viability, precision, and control in molecular payload delivery - unlocking the full potential of gene editing for cell engineering. Mekonos is well positioned to support cell engineering applications across all aspects of therapeutic development - biomanufacturing, cell therapies, drug screening, and disease modeling for regenerative medicine development. Mekonos offers collaborators a scalable solution to seamlessly move from R&D to manufacturing and opens the doors to a new world of possibilities, including complex genetic modifications and challenging cell types currently inaccessible with conventional delivery technologies.
Mekonos
Company Website: https://www.mekonos.com/
Lead Product in Development: N/A Mekonos is developing a platform for cell engineering

Company HQ City

Alameda

Company HQ State

California

Company HQ Country

United States

CEO/Top Company Official

Anil Narasimha

Development Phase of Primary Product

Other/Not Applicable
Primary Speaker
Anil Narasimha, PhD
Co-Founder & Chief Executive Officer
Mekonos
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS